Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...

Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $405 from $400 and keeps a Buy rating on the shares ...

Citi raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $469 from $378 and keeps a Buy rating on the shares post the Q4 ...

The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) reached a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...